Why Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has a 57% chance to Drop?

Why Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has a 57% chance to Drop?

Why Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) has a 57% chance to Drop?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) is expected to announce second quarter financial results after market close (confirmed) on August 17, 2017. The company added about -14.9% percent in value since last earnings when it was at $12.31. Based on the most relevant historical data, there is a 57 percent probability for share price to go down following the next earnings report. Looking further into earnings reaction history, the stock had moved down 4 times out of last 7 quarters. It has topped earnings-per-share estimates 10% of the time in its last 12 earnings reports. It missed earnings on 9 occasions, and it has met expectations 0 time.

Bellicum Pharmaceuticals, Inc. (BLCM) History

Overall, the average earnings surprise was -7.35 percent over the past four quarters. Back on May 08, 2017, it posted earnings per share at $-0.80 which missed the consensus $-0.70 projection (Negative surprise of -13.67%). Revenue came in at $0.13M versus consensus estimate of $0.07M. The stock dropped -3.33% percent the day following the earnings was released, and on 7th day price change was 5.28% percent.

On March 13, 2017, it posted earnings per share at $-0.74 versus the consensus estimate of $-0.71 (Negative surprise of -4.23%). Revenue of $0.08M was below the $0.09M analysts had expected. The stock dropped -4.83% the day following the earnings was released, and on 7th day price change was 8.37%.

On November 09, 2016, it posted earnings per share at $-0.66, missed the consensus estimate of $-0.63 (Negative surprise of -4.10%). Revenue for the quarter was $0.11M while analysts had expected revenues to come in at $0.07M. The stock gained 6.28% the day following the earnings was released, and on 7th day price change was <spanstyle=’color:red;’>N/A.

On December 31, 1969, it posted earnings per share at $-0.61 compared with the consensus estimate of $-0.57 (Negative surprise of -7.39%). That came on revenues of $0.1M for the quarter. Analysts had expected $0.09M in revenue.</spanstyle=’color:red;’>

Bellicum Pharmaceuticals, Inc. (BLCM) Earnings Expectations

In front of Q3 earnings release, Wall Street is expecting earnings per share of $-0.66. The analysts’ current consensus range is $-0.69-$-0.62 for EPS. The market consensus range for revenue is $ N/A-$130k, with an average of $80k.

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) last closed at $12.90, sending the company’s market cap around $395.00M. The consensus 12-month price target from brokerage firms covering the stock is $28.00. The share price has declined -44.18% from its best level in 52 weeks and advanced -5.29% this year. It recently traded in a range of $-$ at a volume of 2,856,309 shares. The stock ended last trading session with the price nearly 30.17% higher for the last 5 trading days, rebounding 32.85% from its 52-week low.

 

Risk Warning: Investing in digital currencies, stocks, shares and other securities, commodities, currencies and other derivative investment products (e.g. contracts for difference (“CFDs”) is speculative and carries a high level of risk. Each investment is unique and involves unique risks.

CFDs and other derivatives are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how an investment works and whether you can afford to take the high risk of losing your money.

Cryptocurrencies can fluctuate widely in prices and are, therefore, not appropriate for all investors. Trading cryptocurrencies is not supervised by any EU regulatory framework. Past performance does not guarantee future results. Any trading history presented is less than 5 years old unless otherwise stated and may not suffice as a basis for investment decisions. Your capital is at risk.

When trading in stocks your capital is at risk.

Past performance is not an indication of future results. Trading history presented is less than 5 years old unless otherwise stated and may not suffice as a basis for investment decisions. Prices may go down as well as up, prices can fluctuate widely, you may be exposed to currency exchange rate fluctuations and you may lose all of or more than the amount you invest. Investing is not suitable for everyone; ensure that you have fully understood the risks and legalities involved. If you are unsure, seek independent financial, legal, tax and/or accounting advice. This website does not provide investment, financial, legal, tax or accounting advice. Some links are affiliate links. For more information please read our full risk warning and disclaimer.